Management of Digitaria insularis in soybean pre-sowing desiccation by ACCase alternative herbicides and its impact on soybean carryover.

The objective of this study was to evaluate the use of alternative herbicides to ACCase inhibitors to control Digitaria insularis (sourgrass) during pre-sowing soybean desiccation. Two field experiments were conducted with two temporal replicates under different climatic conditions, with the following treatments: imazethapyr + glyphosate, clethodim + fluroxypyr, chlorimuron + glyphosate, imazapic + imazapyr, mesotrione + atrazine + glyphosate, tembotrione + atrazine + glyphosate, nicosulfuron + atrazine and imazamox + glyphosate, all of which were composed of a sequential application of glufosinate ammonium. The water stress conditions in experiment 1 compromised the efficacy of acetolactate synthase enzyme (ALS) inhibitor herbicides in the control of sourgrass. Even under water restriction conditions, the treatments containing mesotrione + atrazine + glyphosate and tembotrione + atrazine + glyphosate provided control greater than 80%. In experiment 2, the combination of ALS inhibitors with glyphosate proved to be a great alternative for the management of sourgrass control. All treatments showed no significant phytotoxicity in soybean for either experiment.

Safety and costs of blood transfusion practices in dengue cases in Brazil.

BACKGROUND: Dengue is a public health problem, and noncompliance with World Health Organization (WHO) recommendations for blood transfusion components is frequently reported. Moreover, economic impact studies of the WHO recommendations on the use of blood transfusion are scarce. METHODS: We compared the cost and hospitalization time in a prospective observational study, by following hospitalised patients and analysing their medical records from 2010 and March 2016 to December 2017. We divided the patients into two groups: transfused (with or without WHO criteria for transfusion) and not transfused (with or without WHO criteria for transfusion). Generalised linear modelling was performed to identify the variable that could increase the costs and hospital stay. RESULTS: Among 323 patients, 52 were transfused, of whom 52% without criteria (n = 27), and 271 were not transfused, of which 4.4% (n = 12) with criteria. Hospitalisation costs were 41% higher in the transfused group without criteria than in those with criteria (median US$ 674.3 vs US$ 478 p = 0.293). Patients who were not transfused but met the WHO criteria for transfusion (n = 12) had longer mean hospitalisation time than did those who were not transfused (3.8±3.4 days versus 3.6±3.1 days; p = 0.022). The GLM analysis using hospital stay and costs as the dependent variable explained approximately 33.4% (R2 = 0.334) of the hospitalisation time and 79.3% (R2 = 0.793) of costs. Receiving a transfusion increased the hospitalization time by 1.29 days (p = 0.0007; IRR = 1.29), and the costs were 5.1 times higher than those without receiving blood components (IRR = 5.1; p< 0.001; median US$ 504.4 vs US$ 170.7). In contrast, patients who were transfused according to WHO criteria had a reduction in costs of approximately 96% (IRR = 0.044; p<0.001; ß = -3.12) compared to that for those who were not transfused according to WHO criteria (without criteria). CONCLUSION: Transfusion without following WHO recommendations increased the time and cost of hospitalisation.